Project leaderLaura Soucek
Participating organizationsVHIO, ICREA, Peptomyc
To develop a new generation of peptides targeting the Myc oncoprotein, for oncology treatments. Myc is a central transcription factor that coordinates cell growth and proliferation, the expression of which is unregulated in most human cancers. To inhibit it, Dr. Laura Soucek has designed a Myc dominant negative called Omomyc. The company's mission is to maximize the therapeutic potential of Omomyc, developing it to treats glioblastoma (GBM), non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC) intravenously.
Peptomyc is a biopharmaceutical spin-off of the Vall d’Hebron Institute of Oncology (VHIO) and the Catalan Institution for Research and Advanced Studies (ICREA). The company was founded in Barcelona in December 2014 based on research led by Dr. Laura Soucek over the past 20 years. A licensing agreement has been signed regulating transfer of the technology.
Most significant challenges
The main challenge this spin-off has faced has been transferring the fruit of 20 years of research to market. The facilities the VHIO and ICREA have given have made it possible for the company to not have transfer difficulties. On the regulatory front, Peptomyc will soon conduct non-regulatory preclinical experiments and coordinate execution of regulatory experiments needed to take Omomyc to the clinical-trial phase (phase I/II).
Peptomyc has one patent in progress in Spain to protect the use of peptides derived from Omomyc for oncology. A second patent application has been submitted and PCT to protect new variants of Omomyc. Both patents fall under the framework of the licensing deal signed with VHIO.
In July 2017, Peptomyc closed a series-A round of funding, with participation from ALTA Life Sciences, as well as investors from the seed round (Healthequity and a group of business angels). The company raised €5.2 million in these rounds, including more than €2 million in public funds leveraged from sources like the Ministry of the Economy and Competitiveness Retos program, Neotec-CDTI and Phase I SME Instrument (European Commission).